A recent study showed that a therapeutic antibody targeting KRAS synergistically increased the antitumor activity of gemcitabine by inhibiting RAS downstream signaling in pancreatic cancer with KRAS mutation10. The gene discussed is KRAS; the disease is pancreatic neoplasm.